Skip to main content
Pure Biologics S.A. logo

Pure Biologics S.A. — Investor Relations & Filings

Ticker · PUR ISIN · PLPRBLG00010 LEI · 2594002TXS19AUYHIF82 WAR Manufacturing
Open in API
Filings indexed 515 across all filing types
Latest filing 2024-12-03 Share Issue/Capital Cha…
Country PL Poland
Listing WAR PUR

About Pure Biologics S.A.

https://purebiologics.com/

Pure Biologics S.A. is a biopharmaceutical company engaged in the discovery and development of novel biological drugs and non-systemic therapies. The company leverages its expertise in antibody and aptamer technologies to create innovative treatments. Its therapeutic portfolio is primarily focused on immuno-oncology. A key aspect of its strategy is the development of original, non-generic and non-biosimilar, biological drug candidates.

Recent filings

Filing Released Lang Actions
Warunkowa rejestracja akcji serii J w KDPW - Content (PL)
Share Issue/Capital Change Classification · 95% confidence The document is very short (1117 characters) and announces an action taken by the National Securities Depository (KDPW) regarding the registration of 55,555 shares of the Issuer (Pure Biologics S.A.). It cites the legal basis as the Minister of Finance Regulation concerning current and periodic information provided by issuers. This is a specific regulatory announcement concerning the status of shares, but it is not a full report (like 10-K or IR) nor a standard dividend/insider trade notice. Since it deals with the formal registration/status of securities, it fits best under general Regulatory Filings (RNS) as a specific, non-standard announcement, or potentially Capital/Financing Update (CAP) if the registration implies a new issuance, but RNS is the safer fallback for specific regulatory notices not covered elsewhere. Given the context of share registration and regulatory compliance, RNS is the most appropriate general category for this specific notice.
2024-12-03 Polish
Projekty uchwał NWZ Pure Biologics S.A._27.12.2024
AGM Information Classification · 99% confidence The document text consists of several resolutions ('Uchwała') proposed for an Extraordinary General Meeting ('Nadzwyczajnego Walnego Zgromadzenia') of Pure Biologics S.A. scheduled for December 27, 2024. The content details the proposed agenda items, including the election of the Chairman, adoption of the agenda, a resolution on the continued existence of the company (due to losses exceeding capital thresholds), and crucially, a resolution to approve the sale of rights to specific projects (PBA-0405 and PBA-0111). Documents detailing the agenda, proposed resolutions, and procedural matters for a General Meeting, especially when they include substantive decisions like asset sales requiring shareholder approval, are characteristic of materials prepared for or presented at such a meeting. This aligns best with 'AGM Information' (AGM-R), which covers presentations and materials shared during the Annual General Meeting (or Extraordinary General Meeting in this case). It is not a final report (10-K, IR), an earnings release (ER), or a proxy statement (PSI), but rather the core documentation for the meeting itself.
2024-12-01 Polish
Ogłoszenie o zwołaniu NWZ Pure Biologics S.A._27.12.2024
AGM Information Classification · 99% confidence The document is titled "OGŁOSZENIE ZARZĄDU PURE BIOLOGICS S.A. Z SIEDZIBĄ WE WROCŁAWIU O ZWOŁANIU NADZWYCZAJNEGO WALNEGO ZGROMADZENIA SPÓŁKI" (Announcement of the Management Board of Pure Biologics S.A. regarding the convening of an Extraordinary General Meeting of the Company). It details the date, time, location, and agenda for an upcoming shareholder meeting (Nadzwyczajne Walne Zgromadzenie - Extraordinary General Meeting). This content directly relates to the formal procedures and materials associated with shareholder meetings, specifically the notice of convening the meeting and outlining shareholder rights regarding participation and voting. This aligns best with the definition of AGM Information (AGM-R), which covers presentations and materials shared during the Annual General Meeting (or in this case, an Extraordinary General Meeting, which falls under the same procedural category for notification). It is not a proxy statement (PSI) as it is the initial convening notice, nor is it a declaration of voting results (DVA).
2024-12-01 Polish
Informacja o zwołaniu Nadzwyczajnego Walnego Zgromadzenia Pure Biologics S.A. wraz z treścią projektów uchwał - Content (PL)
AGM Information Classification · 96% confidence The document text is very short (1135 characters) and explicitly states that the management ('Zarząd') is announcing the convening of an Extraordinary General Meeting ('Nadzwyczajnego Walnego Zgromadzenia Spółki') and that the content of the resolutions ('treść projektów uchwał') and the full announcement are attached or available on the company website. This structure—announcing a meeting and providing materials/links—fits the definition of a Report Publication Announcement (RPA) or a general Regulatory Filing (RNS), rather than the AGM materials themselves (AGM-R) or a Proxy Statement (PSI). Given the context of announcing the meeting and attaching related documents, RPA is the most precise fit based on the 'MENU VS MEAL' rule, as it is an announcement *about* the meeting materials.
2024-12-01 Polish
Zawarcie Aneksu do umowy inwestycyjnej z dnia 12 lipca 2024 r. oraz podwyższenie kapitału zakładowego w granicach kapitału docelowego przez Zarząd - Content (PL)
Capital/Financing Update Classification · 98% confidence The document is a formal report from the Management Board ("Zarząd") of a Polish company (Pure Biologics S.A.) detailing an amendment ("Aneks") to a prior Investment Agreement ("Umowa Inwestycyjna"). This amendment concerns the substitution of one investor (eCapital) with another individual (ML) in relation to a planned capital increase ("podwyższeniu kapitału zakładowego"). The text explicitly discusses the terms of financing, the issuance of new shares (Series L, M, N, O), the cancellation of previous board resolutions regarding the share issue, and the subsequent adoption of new resolutions reflecting the change in investor. This content directly relates to changes in the company's capital structure and fundraising activities, making it a Capital/Financing Update.
2024-11-28 Polish
Treść zmienionych postanowień Statutu Spółki Pure Biologics S.A._25.11.2024
Capital/Financing Update Classification · 98% confidence The document text is in Polish and details amendments to the company's Statute ('Zmiany Statutu') resulting from a resolution of an Extraordinary General Meeting ('Nadzwyczajnego Walnego Zgromadzenia'). The core content involves conditional increases in share capital ('warunkowego podwyższenia kapitału zakładowego') through the issuance of new shares ('emisji akcji') linked to subscription warrants ('warrantów subskrypcyjnych'). This directly relates to changes in the company's capital structure and financing activities. The most appropriate category is 'Capital/Financing Update' (CAP), as it describes the mechanics of a capital increase and warrant issuance, which are financing activities, rather than a general regulatory announcement (RNS) or a formal report (10-K/IR). The document is a formal resolution/amendment regarding capital structure changes.
2024-11-26 Polish

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.